European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Bruno C. Medeiros(Stanford Medicine), Robert Lowsky(Stanford University), Jonathan Benjamin(Amgen (United States)), Lü Tian(Shandong University), Linda J. Johnston(Université Bourgogne Franche-Comté), Sally Arai(Stanford Medicine), Ginna G. Laport(Stanford Blood Center), David B. Miklos(Stanford University), J A Shizuru(Stanford University), S Robenson(Stanford University), RS Negrin(Stanford University), W-K Weng(Stanford University)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k